X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!
















Authors
 

Novartis vs Indian Patents Act - Case decoded

Apr 5, 2012

This article describes the case of Novartis' Glivec against the Indian Patent Act.

MNC Pharma: Where is it headed?

Jun 12, 2007

In terms of both the financial performance and the stock price movement, the MNC pharma companies, as compared to their domestic counterparts, seem to have gone on the backfoot. In this article, we shall analyse the reason for the same and what the future holds for these companies going forward.

Pharma: Towards a healthy future?

Dec 28, 2006

While the Sensex made historical highs during 2006, the performance of the BSE Healthcare Index, like in 2005, left a lot to be desired. Nothing highlights this fact more clearly than the following statistic - In the past one year, while the Sensex, albeit hiccups in May 2006, notched up nearly 44% gains, the healthcare index has under performed the benchmark managing to garner only 22%! This is despite the fact that the performance of the pharma industry in 2006 was much better than that in 200

Abbott: What lies ahead?

Aug 24, 2005

With the advent of the product patent law in India, Indian arms of MNC pharma companies will be in the limelight, as they will look to launch patented products from their parents’ folio. Being an MNC pharma company, Abbott also stands to gain from the same. In this article, we take a look at the company’s past performance and what lies for it in the future.

MNC pharma: Seek opportunity!

Nov 24, 2004

According to newspaper reports, a leading consultancy firm has estimated that the Indian pharmaceutical sector will become a US$ 25 bn industry by the year 2012, up from its current levels of about US$ 6.5 bn. According to the report, while the market in India will expand, further growth will be driven by exports of pharmaceutical products. While Indian companies are likely to grab this opportunity with both the hands, in this article we have tried to understand how MNC pharma companies are pois

2QFY05: Pharma sector revisited

Nov 8, 2004

Be it a bull run or a free fall, pharma sector is there for investors rescue in either cases. In the performance review of June quarter, we noticed that the pharma sector cushioned investors from the disgrace of free fall of the market. In this quarter too, the pharma sector has outperformed the Sensex by almost 4%! While the BSE Sensex has risen by almost 16.4% since July 2004, the pharma index is up

Novartis: Growth not visible

Oct 30, 2004

MNC pharma company, Novartis India, declared its 2QFY05 and 1HFY05 results yesterday. The topline of the company has registered a marginal growth in the quarter. However, the bottomline saw a decline of 18% owing to lower other income and higher tax expenses on a YoY basis. The poor performance of the bottomline is despite an operating margin expansion of 780 basis points.

Glaxo: Other income fillip

Oct 29, 2004

MNC pharma major, Glaxo (GSK Pharma), reported 20% growth in revenues in 3QCY04. Consequently, the company finished the nine month period ended September 2004 with revenue growth of nearly 14% YoY. The bottomline of the company grew by almost three fold on back of extraordinary income from sale of its Worli (Mumbai) property. The operating margin also saw an expansion of nearly 7%.

Aventis: Looking healthier

Oct 23, 2004

MNC pharma major Aventis, recently announced its 3QCY04 and 9mCY04 results. During 3QCY04, the topline grew by 13.1% YoY while the bottomline grew by 63% YoY. For the first nine months of the year, while the topline growth was 11.2%, the bottomline grew by an even more impressive 73.7% as compared to same period last year. Cost cutting measures has seen the company improving its operating margins by an astonishing 1120 basis points during the third quarter.

Aventis Pharma 2QFY05 net up 63% YoY

Oct 21, 2004

MNC pharma major Aventis, declared its 3QCY04 and 9mCY04 results. In 3QCY04, the topline grew by 13.1% while the bottomline grew by 63%. For the first nine months of the year the topline growth was 11.2% and the bottomline grew by 73.7%. The operating margins o the company has expanded by almost 11% owing to the cost cutting drive.

Pfizer: Coming back to health

Sep 21, 2004

Pfizer India is one of the leading MNC pharma companies operating in India. It is a 40% subsidiary of the world's largest pharma company Pfizer Inc, which had sales of US$ 40 bn in 2003. It is a leading company in the Indian markets with key brands such as Corex (a cough syrup) and Becosules (a B-complex supplement), the two being brands with a revenue of over Rs 1 bn each. Most of the company’s products are OTC (over the counter) products with strong brand equity.

MNC pharma: The opportunity

Sep 14, 2004

There are many MNC pharma companies operating in India. While some of them have really entrenched themselves in the country, others are involved more in being a trading entity. Companies such as Aventis, Glaxo and Pfizer have full fledged operations in India, others like Abbott, Sanofi, Novartis are more or less trading companies. This is one of the major criteria that also determine the depth of these companies in the Indian market place. In this article, we review the MNC companies that are pr

Performance Summary: Pharma sector

Aug 11, 2004

Pharma sector is generally believed to be a defensive sector, as factors that impact demand and supply for this sector are to an extent, different from factors that impact economic growth. This is not to say that the sector is not impacted by economic performance at all. This, to some extent, is true and is apparent from the graph below. While the BSE Sensex has declined by 9% since April 2004, the pharma index is down only 4% in the same period.

Novartis: Dismal performance continues

Oct 31, 2003

MNC pharma major, Novartis, announced dismal 2QFY04 results yesterday. The company has reported a 5% drop in topline and a 17% decline in bottomline. For 1HFY04, while the net sales have dropped marginally, pressure on margins has resulted in a 9% drop in net profits. In this context, let us briefly evaluate the company’s performance during the period under review.

GSK Pharma: Efficiencies drive growth

Oct 28, 2003

GlaxoSmithKline Pharma (GSK) has announced its 3QFY04 results. Despite a revival in the domestic pharma market, the company has posted a meager 4% growth in topline (GSK had recorded an impressive 10% growth during 2QFY04 when the domestic pharma industry was going through a tough phase). However, improvement in operating efficiencies has helped the company record a robust 55% growth in bottomline. For 9mFY04, GSK has reported a 4% growth in net sales and a 56% rise in net profit.

Aventis Pharma: Strategy paying off

Oct 21, 2003

Aventis Pharma announced its 3QFY04 results last week. While the company has reported a marginal 2% growth in the topline, operating efficiencies have helped it record a sharp 57% rise in bottomline. For 9mFY04 also, the company has reported a 6% and 54% growth in net sales and net profit respectively. In this context, let us take a brief look at the company’s performance.

MNC Pharma: A comparison

Oct 14, 2003

In an article in our series on identifying stocks, we had discussed the key parameters that should be looked into while investing in an MNC pharma stock. In this article, we have analyzed some of the leading MNC pharma companies (GlaxoSmithKline Pharma, Pfizer, Aventis, Novartis and Abbott India) on the basis of some of the parameters that were mentioned in that article. Take a look at the following t

Identifying an MNC pharma stock: Do's and don'ts

Oct 11, 2003

In Views on News, Equitymaster has tried to highlight here some factors one should keep in mind before investing in an Pharmaceuticals company. Know more

GSK Pharma: Gearing for 2005

Oct 7, 2003

GlaxoSmithKline Pharmaceuticals Ltd (GSK) is India’s largest pharmaceutical company with a market share of 7%. Globally, its parent, GlaxoSmithKline Plc is the second largest pharma company. Although GSK’s product portfolio boasts of some of the best-known brands in the domestic market, stiff competition and a slump in the domestic market has stunted the company’s revenue growth in recent months. In this context, let us briefly understand GSK’s business structure and its strategy in view of the

Abbott India: Modest growth

Oct 3, 2003

MNC pharma major, Abbott India has recently announced its 3QFY04 results. While the company registered a modest 7% increase in topline, bottomline shot up by a significant 60%. For 9mFY04, Abbot registered a 5% growth in net sales and 29% rise in net profits. In this context, let us briefly evaluate the company’s performance.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS